中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

163 records (took 0.019 seconds)

    ASSAY FOR THE DIAGNOSIS OF A NEUROLOGICAL DISEASE
    1.
    发明申请
    ASSAY FOR THE DIAGNOSIS OF A NEUROLOGICAL DISEASE 审中-公开
    检测神经系统疾病的诊断

    公开(公告)号：WO2017190834A1

    公开(公告)日：2017-11-09

    申请号：PCT/EP2017/000549

    申请日：2017-05-03

    Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG

    Inventor： ADx NeuroSciences NV ,  VANMECHELEN, Eugeen ,  DE VOS, Ann ,  ENGELBORGHS, Sebastiaan ,  PETERS, Oliver ,  SCHIPKE, Carola

    IPC: G01N33/68

    CPC classification number: G01N33/6896 ,  C12Q2521/537 ,  G01N2333/4703 ,  G01N2333/4709 ,  G01N2333/96472 ,  G01N2800/2821 ,  G01N2800/304 ,  G01N2800/54 ,  G01N2800/56

    Abstract: The present invention relates to a diagnostically useful carrier comprising a means for capturing Neurogranin, a means for capturing BACE1 and preferably a means for capturing one or more additional biomarkers; a kit comprising the diagnostically useful carrier, optionally further comprising a means for detecting Neurogranin, a means for detecting BACE1 and preferably a means for detecting the one or more additional biomarkers; and a method comprising the steps contacting a sample from a subject with a means for capturing Neurogranin, isolating the means for capturing Neurogranin from the sample and contacting a sample from a subject with a means for capturing BACE1 and isolating the means for capturing BACE1 from the sample. The diagnosis aims to distinguish a neurodegenerative disease, preferably mild Alzheimer's disease, and depression with or without cognitive impairment.

    Abstract translation: 本发明涉及诊断上有用的载体，其包含用于捕获神经颗粒素的工具，用于捕获BACE1的工具并且优选用于捕获一种或多种另外的生物标志物的工具; 包含诊断有用载体的试剂盒，任选地进一步包含用于检测神经颗粒素的工具，用于检测BACE1的工具并且优选地用于检测所述一种或多种另外的生物标志物的工具; 以及包括以下步骤的方法：将来自受试者的样品与用于捕获神经颗粒素的工具接触，从样品中分离用于捕获神经颗粒素的工具，并用来自受试者的样品与用于捕获BACE1的工具接触并从用于捕获BACE1的工具 样品。 诊断旨在区分神经退行性疾病，优选轻度阿尔茨海默病和具有或不具有认知障碍的抑郁症。

    ＣＩＤＥＣによるうつ病の検査方法
    3.
    发明申请
    ＣＩＤＥＣによるうつ病の検査方法 审中-公开
    使用CIDEC进行抑制的测试方法

    公开(公告)号：WO2015122499A1

    公开(公告)日：2015-08-20

    申请号：PCT/JP2015/054007

    申请日：2015-02-13

    Applicant: 国立大学法人 群馬大学

    Inventor： 三國　雅彦 ,  宮田　茂雄

    IPC: G01N33/53 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N37/00 ,  C12N15/09

    CPC classification number: G01N33/6896 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/00 ,  G01N2800/304 ,  G01N2800/52

    Abstract: うつ病の重症度を示す客観的なマーカーとして、CIDECの発現量を測定する。さらに、STYXL1、SLC36A1、RNASE1、ARFRP1、BCL11B、SLC35F2、BANP、RAB11FIP4、FYCO1、NIPAL3、RPL23A、RPS2及びSIGIRRからなる群より選ばれる１種又は２種以上の発現量を併せて測定する。これにより、被検動物におけるうつ病の診断及びその重症度評価のための検査方法、うつ病の治療効果の評価方法、並びにうつ病治療薬のスクリーニング方法が提供される。

    Abstract translation: 本发明测量CIDEC作为指示抑郁症严重程度的客观标记物的表达水平。 此外，本发明测量了选自STYXL1，SLC36A1，RNASE1，ARFRP1，BCL11B，SLC35F2，BANP，RAB11FIP4，FYCO1，NIPAL3，RPL23A，RPS2和SIGIRR的一种或多种基因的组合表达水平。 因此，提供了用于诊断和评估测试动物的抑郁症的严重性的测试方法，用于评估治疗抑郁症的功效的方法，以及筛选抑郁症治疗剂的方法。

    COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS
    5.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS 审中-公开
    治疗恶臭症的组合物和方法

    公开(公告)号：WO2013039956A3

    公开(公告)日：2014-05-15

    申请号：PCT/US2012054735

    申请日：2012-09-12

    Applicant: UNIV COLUMBIA ,  SCHMAUSS CLAUDIA ,  LEVINE AMIR

    Inventor： SCHMAUSS CLAUDIA ,  LEVINE AMIR

    IPC: A61K38/00 ,  A61P3/04 ,  A61P25/00

    CPC classification number: A61K31/167 ,  A61K31/138 ,  A61K31/19 ,  A61K31/20 ,  A61K31/4406 ,  A61K45/06 ,  C12Q1/34 ,  G01N2800/304 ,  G01N2800/52 ,  A61K2300/00

    Abstract: The present invention provides, inter alia, methods for enhancing the anti-depressant efficacy of a selective serotonin re-uptake inhibitor (SSRI) in a patient being treated for a mood disorder. These methods include administering to a patient in need thereof a therapeutically effective amount of an SSRI and a therapeutically effective amount of a modulator of histone expression. Also provided are methods for identifying a patient population that suffers from a mood disorder that is more likely to respond to SSRI treatment. Further provided are compositions for treating or ameliorating the effects of a mood disorder.

    Abstract translation: 本发明尤其提供了用于增加选择性5-羟色胺再吸收抑制剂（SSRI）在治疗情绪障碍的患者中的抗抑郁功效的方法。 这些方法包括向有需要的患者施用治疗有效量的SSRI和治疗有效量的组蛋白表达调节剂。 还提供了用于鉴定患有更可能对SSRI治疗作出反应的情绪障碍的患者群体的方法。 还提供了用于治疗或改善情绪障碍的作用的组合物。

    SCREENING ASSAYS FOR COMPOUNDS FOR USE IN THE TREATMENT OF STRESS-RELATED DISORDERS
    6.
    发明申请
    SCREENING ASSAYS FOR COMPOUNDS FOR USE IN THE TREATMENT OF STRESS-RELATED DISORDERS 审中-公开
    用于治疗紧张相关疾病的化合物的筛选测定

    公开(公告)号：WO2013083851A1

    公开(公告)日：2013-06-13

    申请号：PCT/EP2012/074995

    申请日：2012-12-10

    Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

    Inventor： ZIMMERMANN, Nicole ,  ZSCHOCKE, Jürgen ,  REIN, Theo ,  HOLSBOER, Florian

    IPC: G01N33/50

    CPC classification number: G01N33/5058 ,  G01N2333/91017 ,  G01N2800/301 ,  G01N2800/304

    Abstract: The present invention relates to methods of identifying a compound having a therapeutic activity in the treatment of stress-related disorders. The invention also describes a method of providing a compound having a therapeutic activity in the treatment of stress-related disorders. In a further aspect, the invention relates to an antibody or a binding fragment thereof capable of specifically binding to the histone methyltransferase G9a protein for use as a medicament. The present invention also discloses an inhibitory polynucleotide molecule capable of interfering with the expression of the histone methyltransferase G9a protein and a vector comprising such an inhibitory polynucleotide molecule. The invention in a further aspect also relates to a pharmaceutical composition comprising an antibody or binding fragment thereof or an inhibitory polynucleotide molecule as described herein.

    Abstract translation: 本发明涉及鉴定在治疗应激相关疾病中具有治疗活性的化合物的方法。 本发明还描述了一种在治疗应激相关疾病中提供具有治疗活性的化合物的方法。 另一方面，本发明涉及能够特异性结合组蛋白甲基转移酶G9a蛋白用作药物的抗体或其结合片段。 本发明还公开了能够干扰组蛋白甲基转移酶G9a蛋白表达的抑制性多核苷酸分子和包含这种抑制性多核苷酸分子的载体。 本发明的另一方面还涉及包含本文所述的抗体或其结合片段或抑制性多核苷酸分子的药物组合物。

    SYSTEMS AND METHODS FOR CLINICAL EVALUATION OF PSYCHIATRIC DISORDERS
    7.
    发明申请
    SYSTEMS AND METHODS FOR CLINICAL EVALUATION OF PSYCHIATRIC DISORDERS 审中-公开
    心理疾病临床评估系统与方法

    公开(公告)号：WO2013006704A1

    公开(公告)日：2013-01-10

    申请号：PCT/US2012/045562

    申请日：2012-07-05

    Applicant: HUNT, Robert Don

    Inventor： HUNT, Robert Don

    IPC: G01N33/48 ,  G01N33/50 ,  G06F11/00

    CPC classification number: A61B5/4848 ,  A61B5/0022 ,  A61B5/0042 ,  A61B5/0476 ,  A61B5/165 ,  A61B5/168 ,  A61B5/4088 ,  A61B5/6898 ,  A61B5/7282 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2800/30 ,  G01N2800/301 ,  G01N2800/304 ,  G01N2800/305 ,  G06F19/00 ,  G06F19/3456

    Abstract: A method of optimizing the effectiveness of a medication for the treatment of a neurobehavioral or psychiatric disorder in a patient is presented. Medication is administered to a patient. Patient information is obtained and stored in a computer database. Real-time current information is received, for example from a mobile computer device, by the patient relating to (i) medication being taken by the patient; (ii) at least one benefit or lack of benefit of the medication to the patient; (iii) characteristics of one or more current tasks being performed by the patient; and (iv) a current condition of the patient. The effectiveness of the medication is evaluated based on stored patient information and received real-time current information. Accordingly, the dosage or frequency of the medication administered to the patient may be modified, eliminated or maintained.

    Abstract translation: 提出了一种优化用于治疗患者神经行为或精神​​障碍的药物的有效性的方法。 向患者施用药物。 获得患者信息并将其存储在计算机数据库中。 例如来自移动计算机设备的患者接收实时的当前信息，涉及（i）患者服用药物; （ii）向患者提供药物的至少一种益处或缺乏益处; （iii）由患者执行的一个或多个当前任务的特征; 和（iv）患者的当前状况。 基于存储的患者信息和接收的实时当前信息来评估药物的有效性。 因此，施用于患者的药物的剂量或频率可以被修改，消除或维持。

    TREATING MENTAL DISORDERS
    8.
    发明申请
    TREATING MENTAL DISORDERS 审中-公开
    治疗精神障碍

    公开(公告)号：WO2012172340A2

    公开(公告)日：2012-12-20

    申请号：PCT/GB2012/051350

    申请日：2012-06-13

    Applicant: ITH IMMUNE THERAPY HOLDINGS ,  COTTON, Graham ,  WINQVIST, Ola

    Inventor： COTTON, Graham ,  WINQVIST, Ola

    IPC: C07K14/52 ,  A61M1/36 ,  B01J20/32 ,  C07K17/02 ,  G01N33/68

    CPC classification number: C07K14/523 ,  A61M1/3679 ,  B01D15/3823 ,  B01J20/3208 ,  B01J20/3219 ,  B01J20/3274 ,  G01N33/6863 ,  G01N2333/7158 ,  G01N2800/304

    Abstract: A method for treating mental disorders such as schizophrenia, depression and bipolar disorder comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR9, CCR1, CCR3 and/or CCR5 immobilized directly or indirectly on the support thus removing chemokine receptor, optionally CCR9, CCR1, CCR3 and/or CCR5 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.

    Abstract translation: 用于治疗精神障碍如精神分裂症，抑郁症和双相性精神障碍的治疗方法包括将来自患者或受试者的外周血应用于装载有固体支持物的单采血管柱，所述固体支持物包含能够特异性结合趋化因子受体的结合试剂，任选的趋化因子受体CCR9 CCR1，CCR3和/或CCR5直接或间接地固定在支持物上，从而从患者或受试者的外周血中除去趋化因子受体，任选地CCR9，CCR1，CCR3和/或CCR5表达细胞。 还描述了各种伴侣诊断方法和有用的结合试剂。

Patent Agency Ranking